Evidence map›Paper›PMID 28697184›Full record

ReviewNature medicine2017

Insulin action and resistance in obesity and type 2 diabetes.

Michael P Czech

Open access · greenAbstract readReview
In one paragraph

Review in Nature medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 626 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
626citing papers in PubMed, 7 pooled it
55.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

626 citing papers in PubMed, 7 syntheses or guidelines pooled it, 1,239 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. SuFEx-Enabled Reprogramming of Flavonoids for Selective α-Glucosidase Covalent Inhibition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

566 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Michael P CzechProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
University of Massachusetts Chan Medical School · US

Funding

Insulin Signaling and Metabolic Regulation in AdipocytesR37DK030898 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CZECH, MICHAEL P · 1996 to 2021
$7.2M
Oral Delivery Vehicles for RNAi TherapiesR01DK085753 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CZECH, MICHAEL P · 2009 to 2013
$5.9M
Paracrine Signaling by Kupffer Cells in Hepatic Insulin ResistanceR01DK103047 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CZECH, MICHAEL P · 2015 to 2023
$5.0M
Insulin Signaling and Metabolic Regulation in AdipocytesR01DK030898 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CZECH, MICHAEL P · 1986 to 2011
$2.7M
NIDDK NIH HHS R01 DK030898NIDDK NIH HHS R01 DK085753NIDDK NIH HHS R01 DK103047NIDDK NIH HHS R37 DK030898
6 · The paper itself

Abstract

Nutritional excess is a major forerunner of type 2 diabetes. It enhances the secretion of insulin, but attenuates insulin's metabolic actions in the liver, skeletal muscle and adipose tissue. However, conflicting evidence indicates a lack of knowledge of the timing of these events during the development of obesity and diabetes, pointing to a key gap in our understanding of metabolic disease. This Perspective reviews alternate viewpoints and recent results on the temporal and mechanistic connections between hyperinsulinemia, obesity and insulin resistance. Although much attention has addressed early steps in the insulin signaling cascade, insulin resistance in obesity seems to be largely elicited downstream of these steps. New findings also connect insulin resistance to extensive metabolic cross-talk between the liver, adipose tissue, pancreas and skeletal muscle. These and other advances over the past 5 years offer exciting opportunities and daunting challenges for the development of new therapeutic strategies for the treatment of type 2 diabetes.

Indexed as

Insulin ResistanceAdipose TissueDiabetes Mellitus, Type 2HumansInsulin-Secreting CellsLiverMetabolic SyndromeMuscle, SkeletalObesitySignal Transduction

Identifiers

PMID28697184
PMCPMC6048953
OpenAlexW2736294384

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.